반응형

medical device 91

[Emergo, UL] Article 16(4) MDR & IVDR Certification: What Medical Device Manufacturers Need to Know

As Notified Bodies (NBs) in the European Union (EU) begin to roll out Article 16(4)  of the European Medical Devices Regulation 2017/745 (MDR) and the European In-vitro Diagnostic Medical Device Regulation 2017/746 (IVDR)  certification schemes, we at Emergo by UL share our insights on the requirements set out in Article 16 and their applicability to importers, distributors and other natural or ..

뉴스 보고서 2025.04.07

[Emergo, UL] What is a cognitive walkthrough, and why are they beneficial to medical device development?

Addressing potential usability issues early in the human factors engineering (HFE) process can save your team time and money over the course of development while providing evidence of a robust human factors process to regulatory agencies. Cognitive walkthroughs are a powerful method to identify potential usability issues in early development stages when initial decisions about design directions ..

뉴스 보고서 2025.04.04

[Emergo, UL] US FDA Warning Letters: Considerations for LDTs including Timelines

Importance of reviewing warning lettersBy reviewing relevant U.S. Food and Drug Administration (FDA) warning letters, manufacturers can better understand areas of frequent concern related to quality management systems (QMS) and regulatory affairs. This can allow companies to focus on areas of highest risk as they continually assess and improve their internal procedures and processes. It also hel..

뉴스 보고서 2025.04.03

[Emergo, UL] Health Canada Continues to Actively Monitor Supply of Medical Devices

Legislative background on shortagesOn March 2, 2022, amendments to the legislation in Canada, Medical Devices Regulations (SOR/98-282, Part 1, Sections 62.21 to 62.26) came into force. These provisions discuss the notification of shortages to the regulator Health Canada. If an explicit device is delineated on the “List of Medical Devices- Notification of Shortages” and the manufacturer or import..

뉴스 보고서 2025.03.21

[Emergo, UL] IMDRF Updates Terminologies for Categorized Adverse Event Reporting

The technical document Terminologies for Categorized Adverse Event Reporting (AER): Terms, Terminology and Codes has been updated by The International Medical Device Regulators Forum (IMDRF) Adverse Event Terminology working group (AET WG). The current update consists of 36 newly added terms, changes to 56 existing terms and the retirement of eight terms. Release notes that provide a high-level ..

뉴스 보고서 2025.03.20

[Emergo, UL] IMDRF Releases Key Guidance Documents for Medical Device Software

The International Medical Device Regulators Forum (IMDRF) released two key documents related to medical device software: Good machine learning practice for medical device development: Guiding principles (IMDRF/AIML WG/N88 FINAL:2025); and Characterization Considerations for Medical Device Software and Software-Specific Risk (IMDRF/SaMD WG/N81 FINAL:2025). These documents are aimed at improving g..

뉴스 보고서 2025.02.06

[Emergo, UL] US FDA Rules for Notification of Discontinuation or Meaningful Interruption in Manufacturing

This month, the U.S. Food and Drug Administration (FDA), finalized guidance requiring manufacturers to notify them of discontinuations or meaningful interruptions in manufacturing for many devices during or in advance of a public health emergency (PHE). This relatively new authority was established through the 2020 CARES Act and amended by the 2023 Omnibus Consolidated Appropriations Act, alteri..

뉴스 보고서 2025.02.04

[Emergo, UL] Webinar: Determining when to utilize the Pre-Submissions Q-Submission (Pre-Sub) Process

Emergo에서 아래와 같이 웨비나를 개최한다.​▶ 주제: Determining when to utilize the pre-submissions Q-submission (Pre-Sub) Process▶ 일시: 2025년 02월 12일 CST 9시 (한국시간: 02월 13일 00시) In many cases, a manufacturer must submit a marketing submission (such as a 510(k)) to the U.S. Food and Drug Administration (FDA) and have it authorized before they can start selling that device in the U.S. But what if a manufacturer has q..

[Emergo, UL] Malaysia MDA Announces Agreement Between Malaysia and China

BackgroundThe Chief Executive, Dr. Muralitharan Paramasua, of the regulator in Malaysia, the Medical Device Authority (MDA), hosted the 2025 keynote address (January 14).Many programs were presented: e-labeling, UDI, import permit, guidance documents, Medcast 3.0, additional recognized ASEAN countries, and Class A fees. This update focuses on one of the global harmonization/regulatory reliance i..

뉴스 보고서 2025.01.24

[Emergo, UL] MHRA Releases Suite of Guidance for New Post-Market Surveillance Regulation

The Medicines and Healthcare products Regulatory Agency (MHRA) announced the release of a suite of post-market surveillance (PMS) guidance (January 15) in alignment with The Medical Devices (Post-market Surveillance Requirements) (Amendment) (Great Britain) Regulations 2024. BackgroundAs Emergo by UL reported last month, the amendment introduces new and enhanced PMS requirements for manufacturer..

뉴스 보고서 2025.01.23
반응형